| abstract |
An Annexin A5 variant, comprising one or more RGD (Arg-Gly-Asp) sequences, is suitable for use in the treatment of a disease in mammals, including humans, wherein augmentation of phagocytosis is a desired effect of treatment. The Annexin A5 variant can e.g. be used in the treatment of chronic inflammatory diseases such as atherosclerotic plaque or in the treatment of COPD. At least one RGD sequence may substitute sequences of three amino acids within the range 1-19or other regions of the amino acid sequences of Annexin A5; alternatively one or more RGD sequences may be part of an extension at the N-terminal side. |